文献速递神经肿瘤

胱硫醚作为体内磁共振波谱检测1p/19q共缺失胶质瘤的标志物

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
PubMed 文献 · Neuro Oncol · 2019-01-01

研究结合体内1H磁共振波谱(MRS)与液相色谱-质谱(LC-MS)分析人低级别胶质瘤活检组织,首次在1p/19q共缺失胶质瘤中体内检测到胱硫醚选择性蓄积;定量PCR显示共缺失胶质瘤中PHGDH和CTH表达较非共缺失者低40-50%,提示胱硫醚可能作为无创治疗反应标志物。

要点

  • 首次通过MRS在体内检测到1p/19q共缺失胶质瘤中胱硫醚的选择性蓄积。
  • 共缺失胶质瘤中PHGDH和CTH表达较非共缺失者低40-50%。
  • 结果提示共缺失胶质瘤对丝氨酸和谷胱甘肽耗竭存在选择性脆弱性。

核心结论

  • 结果提供强证据表明1p/19q共缺失胶质瘤对丝氨酸和谷胱甘肽耗竭存在选择性脆弱性,并提示胱硫醚可能作为治疗反应的无创标志物。

研究设计与样本

  • 研究纳入65例低级别胶质瘤受试者,其中31例接受MRI/MRS检查,47份脑肿瘤组织样本进行LC-MS分析,33份样本进行定量PCR基因表达分析,并在1p缺失细胞模型中进行代谢示踪实验。

主要发现

  • 在1p/19q共缺失胶质瘤中首次通过MRS实现胱硫醚的体内检测。
  • 胱硫醚选择性蓄积见于共缺失胶质瘤的体内检测、脑组织样本以及携带1p上丝氨酸和胱硫醚通路基因PHGDH和CTH杂合缺失的细胞中。
  • 定量PCR分析显示,1p/19q共缺失胶质瘤中PHGDH和CTH表达均较非共缺失者低40-50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Codeletion of chromosome arms 1p and 19q (1p/19q codeletion) highly benefits diagnosis and prognosis in gliomas. In this study, we investigated the effect of 1p/19q codeletion on cancer cell metabolism and evaluated possible metabolic targets for tailored therapies. METHODS: We combined in vivo 1H (proton) magnetic resonance spectroscopy (MRS) measurements in human gliomas with the analysis of a series of standard amino acids by liquid chromatography-mass spectroscopy (LC-MS) in human glioma biopsies. Sixty-five subjects with low-grade glioma were included in the study: 31 underwent the MRI/MRS examination, 47 brain tumor tissue samples were analyzed with LC-MS, and 33 samples were analyzed for gene expression with quantitative PCR. Additionally, we performed metabolic tracer experiments in cell models with 1p deletion. RESULTS: We report the first in vivo detection of cystathionine by MRS in 1p/19q codeleted gliomas. Selective accumulation of cystathionine was observed in codeleted gliomas in vivo, in brain tissue samples, as well as in cells harboring heterozygous deletions for serine- and cystathionine-pathway genes located on 1p: phosphoglycerate dehydrogenase (PHGDH) and cystathionine gamma-lyase (CTH). Quantitative PCR analyses showed 40-50% lower expression of both PHGDH and CTH in 1p/19q codeleted gliomas compared with their non-codeleted counterparts. CONCLUSIONS: Our results provide strong evidence of a selective vulnerability of codeleted gliomas to serine and glutathione depletion and point to cystathionine as a possible noninvasive marker of treatment response.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Branzoli F, Pontoizeau C, Tchara L, et al. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro Oncol. 2019. PMID: 30726924. doi:10.1093/neuonc/noz031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。